The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016–2020
Open accessAbstract
The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous CBTRUS reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.83 per 100,000 population (malignant AAAIR=6.94 and non-malignant AAAIR=17.88). This overall rate was higher in females compared to males (27.85 versus 21.62 per 100,000) and non-Hispanic persons compared to Hispanic persons (25.24 versus 22.61 per 100,000). Gliomas accounted for 26.3% of all tumors. The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (14.2% of all tumors and 50.9% of all malignant tumors), and the most common predominantly non-malignant histopathology was meningioma (40.8% of all tumors and 56.2% of all non-malignant tumors). Glioblastomas were more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.13 per 100,000 population. There were 86,030 deaths attributed to malignant brain and other CNS tumors between 2016 and 2020. This represents an average annual mortality rate of 4.42 per 100,000 population and an average of 17,206 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.7%, for a non-malignant brain and other CNS tumor the five-year relative survival rate was 91.8%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Anaplastic oligodendrogliomas (AOs) are central nervous system (CNS) World Health Organization (WHO) grade 3 gliomas characterized by isocitrate dehydrogenase (IDH) mutation (m)IDH and 1p/19q codeletion.”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Self-citationPermutation tests for joinpoint regression with applications to cancer rates
Kim, H.-J., Fay, M. P., Feuer, E. J., & Midthune, D. N. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z · Cited by 6,318
Simple Features for R: Standardized Support for Spatial Vector Data
Pebesma, E. (2018) · The R Journal · doi:10.32614/rj-2018-009 · Cited by 4,701
Erratum to: The 2007 WHO classification of tumours of the central nervous system
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-156115 · Cited by 4,442
The epidemiology of glioma in adults: a "state of the science" review
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou087 · Cited by 2,220
Self-citationOstrom, Q. T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou223 · Cited by 1,718
Self-citationInternational Classification of Diseases for Oncology
Trott, P. A. (1977) · Journal of Clinical Pathology · doi:10.1136/jcp.30.8.782-c · Cited by 1,676
Research works printed but not linked: 14
- Louis, 2016, WHO Classification of Tumours of the Central Nervous System
- Centers for Disease Control and Prevention National Center for Health Statistics, 2023, National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: U.S. Cancer Statistics Incidence Analytic Database – 2001-2020
- Surveillance Epidemiology and End Results (SEER) Program, SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2020) <Katrina/Rita Population Adjustment>
- 2017, International Incidence of Childhood Cancer, Volume III.
- Swerdlow, 2007, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition
- Kleihues, 2000, Tumours of the nervous system: World Health Organization classification of tumours.
- Ferlay, 2019, Histological groups
- Central Brain Tumor Registry of the United States SEER*Stat Database, 2023, CDC National Program of Cancer Registries and NCI Surveillance, Epidemiology and End Results Incidence Data, 2022 submission (2000–2020)
- 2023, Joinpoint Regression Program, Version 5.0.2.0; Statistical Methodology and Applications Branch, Surveillance Research Program
- Neff, 2022, prevEst (version 2.0)
- Surveillance Epidemiology and End Results (SEER) Program, 2022, SEER*Stat Database: Incidence - SEER Research Plus Data, 8 Registries, Nov 2021 Sub (1975-2019) - Linked To County Attributes - Total U.S., 1969-2020 Counties
- Central Brain Tumor Registry of the United States SEER*Stat Database, 2022, CDC National Program of Cancer Registries and NCI Surveillance, Epidemiology and End Results Incidence Data, 2021 submission (2000–2019)
- Bray, 2017, Data Comparability and Quality
- Johnson, 2007, The 2007 Multiple Primary and Histology Coding Rules.
Cited by
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Price, M., Ballard, C., Benedetti, J., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., Barnholtz-Sloan, J. S., & Ostrom, Q. T. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae145 · Cited by 526
Self-citationMechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Large language models as a diagnostic support tool in neuropathology
Hewitt, K. J., Wiest, I. C., Carrero, Z. I., Bejan, L., Millner, T. O., Brandner, S., & Kather, J. N. (2024) · The Journal of Pathology: Clinical Research · doi:10.1002/2056-4538.70009 · Cited by 27
Liu, T., Lin, Y.-C., Chang, P.-C., Hueng, D.-Y., & Li, Y.-F. (2025) · Discover Oncology · doi:10.1007/s12672-025-02662-5 · Cited by 4
Metadata
- Authors
- Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S.
- Affiliations
- Duke University (US)
- Central Brain Tumor Registry of the United States (US)
- Central Brain Tumor Registry of the United States , Hinsdale, IL , USA
- Corresponding author
- Ostrom, Quinn T
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-10-04
- Volume
- 25
- Issue
- Supplement_4
- Pages
- iv1-iv99
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC10550277
- OpenAlex
- W4387329303
- Cited by
- 1,294
- References
- 55
- Citations by year
- 2026: 347 · 2025: 440 · 2024: 329 · 2023: 74
- FWCI
- 206.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuro-Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention (75D30119C06056)
- American Brain Tumor Association
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Clinical Neurology › Meningioma and schwannoma management
- Keywords
- primary brain tumors, central nervous system tumors, incidence, mortality, glioblastoma, meningioma, glioma, pediatric brain tumors, relative survival, sex differences, racial and ethnic disparities, age-standardized rates, cancer registry data
- MeSH terms
- Adolescent, Brain, Brain Neoplasms, Child, Female, Glioblastoma, Humans, Male, Meningeal Neoplasms, Meningioma, Registries, United States, Incidence, Central Nervous System Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016–2020. https://app.cochat.ai/papers/10.1093/neuonc/noad149
- The paper
- Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2023). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016–2020. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad149
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.